ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler has been appointed to the newly created position of Chief Operating Officer (COO), ICON plc.
Dr. Cutler joined ICON in November 2011 as Group President, Clinical Research Services. In his new role as COO, Dr. Cutler has responsibility for all of ICON’s operational units, covering Early Phase, Clinical, Laboratories, Commercialisation and Outcomes and DOCS FSP & resourcing. Dr Cutler will also take responsibility for ICON’s sales and marketing and strategic alliance teams.
Within Dr. Cutler’s team, Dr. Nuala Murphy has been appointed President, ICON Clinical Services and Mr. Jim Miskel has been appointed Executive Vice President & General Manager, ICON Laboratory Services.
Dr. Murphy joined ICON in 2012 as Executive Vice President, Global Clinical Operations and Data Management, bringing to ICON over 22 years’ experience within the pharmaceutical and CRO industries. In her new role, Dr. Murphy will oversee ICON’s global clinical services, comprising clinical and data operations, study start-up, project management, clinical risk management, technology services and clinical scientific operations.Mr. Miskel joined ICON in November 2013 and will lead ICON’s newly combined Central and Bioanalytical laboratories group. He brings a wealth of laboratory and pharmaceutical industry experience to ICON, having previously held senior positions with Harlan Laboratories, MDS Pharma Services, Wyeth Pharmaceuticals and McKinsey & Company. Commenting on the appointments, Ciaran Murray, Chief Executive Officer, ICON plc, said: “We continually review our structure to ensure that as the market evolves, our organisation can continue to provide customers with innovative and integrated solutions across our various service lines and business units. Bringing all operational units under Steve’s leadership will allow us to further enhance the support we can offer to our customers’ development programs. I would like to congratulate Steve, Nuala and Jim on their new roles and wish them every success in the future.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts